Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Lymphatic Metastasis 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × DEAE-Dextran × Genitourinary × Clear all
NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
6 enrolled 7 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04779489 2024-02-06

CIRTiN-BC

University of Texas Southwestern Medical Center

Phase NA Terminated
1 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡